فهرست مطالب
Iranian Journal of Blood and Cancer
Volume:8 Issue: 3, Sep 2016
- تاریخ انتشار: 1395/08/05
- تعداد عناوین: 8
-
-
Pages 63-67BackgroundPlatelets rapidly lose their qualities usually after 5 day of storage. Different standard methods have been recommended to check the quality of platelets during storage which some of them show better correlation with other quality markers during storage. The purpose of this study was to demonstrate if platelet factor 3 (PF3) assay could be an indicator of storage lesion and provide a significant correlation with other quality markers during long-term storage of platelet concentrates (PC) up to 11 days.MethodsTwelve random units of PC were placed in a standard platelet incubator under continuous agitation at 22-24°C for eleven days. Samples were taken on days 1, 3, 5, 8 and 11. Parameters such as pH, glucose, lactate dehydrogenase (LDH), platelet count of the bags, mean platelet volume (MPV) and platelet distribution width (PDW) and PF3 were measured. The correlation coefficient of PF3 and pH with the abovementioned parameters was evaluated.ResultsThe mean percentage of changes for PF3, pH, glucose, LDH, platelet count, MPV and PDW on day 11 compared to the first day were found to be 61, 15, 52, 440, 19, 18 and 39%, respectively. After LDH, PF3 had the highest change relative to the other markers. PF3 demonstrated better correlation with glucose, platelet count, MPV and PDW compared with pH during long-term PC storage.ConclusionPlatelet factor 3 based-clotting time assay could be a potential candidate for monitoring the quality of PC due to apparent trend of its changes during storage with better correlation between the quality markers.Keywords: Platelet concentrate, Platelet factor 3, pH, LDH, MPV, Platelet storage lesions, Quality marker, Platelet recovery
-
Pages 68-71BackgroundDiffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes. It is known as a heterogeneous disease with variable therapeutic responses and alternative therapies. Morphological and immunophenotypical evaluation of the biopsy specimens can help diagnose DLBCL.MethodsIn the current study, 44 patients were chosen from Shaheed Sadoghi Hospital (20102013), central Iran. Immunohistochemical method was used for detecting biomarkers such as CD2, CD3, CD20 and CD45.ResultIn this study, 54.5% of the patients were men and 45.5% were women. Most of the patients were 40-50 years old. Moreover, 10 (22.7%) patients had lymph node metastasis and 6 (13.6%) patients had stomach involvement. Positive expression of CD45 and CD20 biomarkers were expressed in 100% and 97.7% of the patients. Positive expression of CD3 and CD2 was expressed in 40.9% and 81.8% of the patients, respectively. C-expression of CD45 and CD20 biomarkers was seen in 43 patients. Moreover, there was no relation between biomarkers and sex and age (P>0.05).ConclusionThe result of this study showed that high number of CD45 and CD20 have been seen in Irans population. Moreover expression of CD20 and CD45 is different as compared with other populations. It seems that these differences can be due to ethnic groups and nature of malignant cells.Keywords: Diffuse large B cell lymphoma_CD20_CD45_CD3_CD2
-
Pages 72-74BackgroundBleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor eight inhibitor bypassing agent). No standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. We suggested that history of the patients response and also their preference could be a reliable method for assessing the efficacy of bypassing agents; therefore, we designed a multi-centric discrete choice experiment study to assess the factors that affect the efficacy of bypassing agents.MethodsHemophilic patients older than 2 years with inhibitors who required bypassing agents for the treatment of bleeding episodes were eligible to participate in the study. Patients preference toward treatment with either Feiba or Aryoseven was measured with a DCE (discrete choice experiment) design on a phone interview.Results80 patients were enrolled from 5 centers in Iran. At enrollment, the mean age was18.6 years (range, 2-50 years). 47 patients (58%) preferred to receive FEIBA, 21 patients (21.2%) favored Aryoseven and 12 (14.8%) patients claimed no difference between the two products.ConclusionOur results indicated that according to the DCE method, patients preferred Feiba to Aryoseven while the main reason was their higher efficacy. In addition, adverse reactions in both groups were almost equal. As a result, it seems that presence of both products in the market for hemophilic patients with inhibitors is absolutely essential.Keywords: Hemophilic patients, Patient's response, Bypassing agents
-
Pages 75-79BackgroundThe oncologic behavior of mucinous adenocarcinoma (MA) of colorectal differs from non-mucinous adenocarcinoma (NMA). MA is more advanced at diagnosis and has a poorer prognosis than NMA. We aimed to evaluate prognostic factors and survival rate in patients with MA compared with NMA in Western Iran.MethodsDuring 2008-2015 in a retrospective study, 83 patients with CRC referred to the Oncology Clinic in Kermanshah, Iran. Binary logistic regression analysis was used for the correlation between risk variables with the type of pathology.ResultsThe mean follow-up was 32 months (range, 12-72 months) and in this interval, there were 26 deaths and 3 patients were lost to follow-up and therefore, were omitted them from survival analysis. There was no significant correlation between NMA and MA with sex, degree of differentiation of tumor, tumor site, tumor size, KRAS mutation and lymph node metastasis, but a significant correlation was observed with age (PConclusionThe prevalence of NMA in CRC was more than MA. In this study, the MA patients had lower age and more risk of recurrence compared to NMA patients and unlike other studies, 5-year survival rate was significantly higher in NMA patients than that in MA patients.Keywords: Colorectal cancer, Survival, Mucinous adenocarcinoma, Non, mucinous adenocarcinoma, Age
-
Pages 80-85BackgroundThe development of anti-red blood cell alloantibodies remains a major problem in transfusion of blood in thalassemia major patients. Also, Autoantibodies can result in clinical hemolysis and difficulty in cross-matching blood. We studied the frequency of red blood cell alloimmunization and autoimmunization among thalassemia patients who received regular transfusions in Ilam province of Iran.MethodsThis study was carried out on 110 multiply transfused patients with thalassemia major. The saline method, Albumin method, direct/indirect coombs and Three cell panel test used for detection of red blood cell alloantibody/ autoantibody.Results12 patients out of total 110 patients (10.9 %) developed alloantibodies and 2 (1.81 %) developed autoantibodies. Rh and Kell blood group system alloantibodies were most commonly found, with the majority of patients being transfused with blood matched for ABO and D antigens only.ConclusionThis study suggests screening RBC antigens prior to transfusion. Our findings accentuate the necessity of antigen typing of supposed to be transfused red blood cells and screenings tests before the first transfusion, at least for Rh (Rh system) and Kell (Kell system) antigens.Keywords: Alloimmunization, Autoimmunization, Thalassemia, Transfusion
-
Pages 86-87Acute leukemia which is the most common cancer in children is a heterogeneous group of clonal malignancies. The conversion of the leukemic cell lineage during the course of the disease or later is termed lineage switch. It has been rarely reported in the literature. In leukemia lineage switch, conversions from lymphoblastic leukemia to myeloid leukemia or vice versa are reported. Herein, we report a 7-year-old child with acute lymphoblastic leukemia which switched to acute myeloid leukemia upon relapse.Keywords: Leukemia, Children, Cell lineage